Details of the Drug Combination

General Information of Drug Combination (ID: DCKOM02)

Drug Combination Name

Hepzato PMID28870136-Compound-43

Indication

Disease Entry	Status	REF
Colon carcinoma	Investigative	[1]

Component Drugs

Hepzato DM2AZPP

PMID28870136-Compound-43 DMWGV8N

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: KM12

Zero Interaction Potency (ZIP) Score: 4.99

Bliss Independence Score: 8.28

Loewe Additivity Score: 2.18

LHighest Single Agent (HSA) Score: 2.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Anaplastic large cell lymphoma	DCFWGID	SR	Investigative	[4]
Adenocarcinoma	DCHR577	A549	Investigative	[5]
Adenocarcinoma	DC6KIMC	SW-620	Investigative	[5]
Adenocarcinoma	DCV6U9T	HT29	Investigative	[5]
Malignant melanoma	DC7UA4S	LOX IMVI	Investigative	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976